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Summary
Objective: Although SOX9 is a key molecule for chondrogenic differentiation, little is known about the upstream signal. The present study
attempted to identify transcription factors to induce SOX9 expression and examined the mechanism.
Methods: Sequences of about 1 kb of 50-end ﬂanking regions were compared between human and mouse SOX9 genes. In vivo localization
was examined by immunohistochemistry in the limb cartilage of fetal mice. Promoter activities of the SOX9, SOX6, and type II collagen
(COL2A1) genes were determined in human non-chondrogenic HeLa cells and mouse chondrogenic ATDC5 cells transfected with a lucifer-
ase-reporter gene containing the promoter fragments. ProteineDNA binding was examined by electrophoretic mobility shift and chromatin
immunoprecipitation assays. The chondrogenic differentiation was assessed by endogenous SOX9, SOX6, and COL2A1 mRNA levels,
and by Alcian blue staining and alkaline phosphatase activity.
Results: Among transcription factors whose binding motifs were identiﬁed in the highly-conserved regions between human and mouse SOX9
promoters, a nuclear factor kappa B (NF-kB) member RelA strongly activated the promoter activity. RelA and SOX9 were co-localized in the
limb cartilage. Deletion, mutagenesis, and tandem-repeat analyses identiﬁed the core region responsive to RelA at the NF-kB binding motif to
be around 250 bp of the human SOX9 promoter, and this was conﬁrmed to show speciﬁc binding to RelA. RelA induced the chondrogenic
differentiation parameters in HeLa and ATDC5 cells.
Conclusion: We have identiﬁed RelA as a transcriptional factor for SOX9 induction and chondrogenic differentiation via binding to an NF-kB
binding motif in the SOX9 promoter.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Skeletal development is initiated by the recruitment of undif-
ferentiated mesenchymal cells into condensations, which
differentiate into pre-chondrocytes and then chondrocytes
that produce cartilage-speciﬁc extracellular matrix proteins
like type II collagen (COL2A1)1. Sex-determining region
Y-type high mobility group box 9 (SOX9) is expressed in
the mesenchymal cells, pre-chondrocytes and chondro-
cytes2,3, and functions as a master transcriptional activator
of COL2A1 and other chondrocyte-speciﬁc matrix proteins,
in cooperation with the co-factors SOX6 and L-SOX54e9.
Expressions of the SOX6 and L-SOX5 are also controlled
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1065essential for multiple steps in the chondrogenic differentia-
tion pathway: conditional ablation of the SOX9 gene in the
limb buds before mesenchymal condensation resulted in
a complete absence of chondrocytes, whereas the condi-
tional ablation after mesenchymal condensation resulted
in a severe generalized chondrodysplasia10e12. In humans
as well, heterozygous mutations of the SOX9 gene cause
a severe chondrodysplasia, known as campomelic dyspla-
sia11,13. Furthermore, we previously reported that SOX9 in
combination with SOX6 and L-SOX5 (the SOX trio) stimu-
lated chondrogenesis even from non-chondrogenic cells
of mouse and human origins, implicating a possible clinical
application of this signal to cartilage regeneration14. Despite
the substantial information about the expression proﬁles
and the target genes of SOX9, little is known about the up-
stream signaling or the functional regulation of the SOX9
promoter. To identify transcription factors that induce
SOX9 expression, the present study initially compared the
genomic sequences of proximal promoter regions between
human and mouse SOX9 genes, and identiﬁed several
highly-conserved regions containing putative transcription
1066 M. Ushita et al.: Transcriptional induction of SOX9 by NF-kB family member RelA in chondrogenic cellsfactor-binding motifs. Among the candidate transcription
factors, our further analyses found that nuclear factor kappa
B (NF-kB) family member RelA (NF-kB p65) most strongly
activated the human SOX9 promoter activity.
The NF-kB family of transcription factors plays a crucial role
in a broad range of biological processes, including immune re-
sponses, inﬂammation, proliferation, differentiation and apop-
tosis15e17. The family includes RelA, RelB, Rel, p105/p50 and
p100/p52, each of which contains aRel homology domain that
mediates DNA binding and dimerization. Numerous studies
have established that IkB proteins are phosphorylated and
degraded by a large protein complex IkB kinase (IKK) in
response to several signals, thereby allowing freeNF-kBcom-
plexes to translocate from the cytoplasm into the nucleus,
leading to target gene transactivation18,19. The NF-kB family
genes are expressed in the chick limb cartilage, and the block-
age of the NF-kB activity caused the arrest of the limb
outgrowth20. The IKKa-deﬁcient mice also exhibited suppres-
sion of limb outgrowth21,22. Since these lines of evidence im-
plicate the interaction between NF-kB and SOX9 signals
during skeletal development, the present study investigated
the mechanism underlying the transcriptional regulation of
the SOX9 promoter by RelA.Materials and methodsCOMPARISON OF THE PROXIMAL PROMOTER SEQUENCES
OF THE HUMAN, MOUSE AND CHICK SOX9 GENESWe compared the sequences of the 50-end ﬂanking regions relative to the
transcription start site among 4 kb human, 4 kb mouse and 300 bp chick
SOX9 gene, using BLASTN search23. The detected sequences were aligned
by the Vector-NTI software (Invitrogen), and the transcription factor-binding
motifs were predicted using the TFSEARCH web site (Computational
Biology Research Center, AIST, Japan).CELL CULTURESThe human epithelial cell line HeLa (RIKEN Cell Bank, Tsukuba, Japan)
was cultured in high-glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM)
with 10% fetal bovine serum (FBS). Mouse chondrogenic ATDC5 cells
(RIKEN Cell Bank) were grown and maintained in DMEM/F12 (1:1) with
5% FBS. To induce chondrogenic differentiation, ATDC5 cells were cultured
in the presence of insulin-transferring-sodium selenite media supplement
(ITS) (Sigma) for 3 weeks and replaced by aMEM/5% FBS with 4 mM inor-
ganic phosphate (Pi) for 2 d24.CONSTRUCTION OF EXPRESSION VECTORSFull-length human cDNA sequences of the transcription factors were poly-
merase chain reaction (PCR)-ampliﬁed and cloned into pCMV-HA vector
(Clontech, Palo Alto, CA, USA). The Gene Bank access numbers are as fol-
lows: NFAT1 NM_012340.3, NFAT2 NM_006162.3, NFAT3 NM_004554.4,
NFAT4 NM_004555.2, NFAT5 NM_138714, Fos NM_005252.2, Jun
NM_002228.3, Fra-1 NM_005438.3, RelA NM_021975.2, RelB NM_0065
09.2, Rel NM_002908.2, p105 NM_003998.2, p100 NM_001077493.1,
ATF1 NM_005171.3, ATF2 NM_001880.2, ATF4 NM_001675.2, ATF6
NM_007348.2, ATF7 NM_001130059.1, CREB NM_004379.2, C/EBPa
NM_004364.2, C/EBPb NM_005194.2, C/EBPd NM_005195.3, C/EBP3
NM_001805.2, GATA-1 NM_ 002049.3, GATA-2 NM_032638.3, GATA-3
NM_001002295.1, GATA-4 NM_002052.3, GATA-5 NM_080473.4, GATA-6
NM_005257.3. The primer sequences are available upon request.LUCIFERASE ASSAYThe human SOX9 promoter region from 927 to þ84 bp relative to the
transcriptional start site (TSS) was obtained by PCR using human genomic
DNA as a template and were cloned into the EcoRI and HindIII sites of the
modiﬁed pGL3 vector containing additional cloning sites between the XhoI
and HindIII sites of the original plasmid, the pGL3-basic vector (Promega,
Madison, WI, USA). Deletion and mutation constructs were created by
PCR technique. Tandem-repeat constructs were created by ligating the dou-
ble strand oligonucleotides into EcoRI site of the modiﬁed pGL3 vector.
Transfection of HeLa and ATDC5 cells was performed in quadruplicate in48-well plates using FuGENE 6 transfection reagent (Roche, Mannheim,
Germany): FuGENE 6 with a total amount of 150 ng of plasmid DNA,
100 ng of pGL3 reporter vector, 50 ng of effector vector, and 4 ng of pRL-
TK vector (Promega) for internal control per well. Cells were harvested
48 h after the transfection. The luciferase assay was performed with
a dual-luciferase-reporter assay system (Promega) using a GloMax 96 Mi-
croplate Luminometer (Promega). The results were shown as the ratio of
the ﬁreﬂy activities to the renilla activities. For the SOX6 promoter assay, a lu-
ciferase-reporter construct containing the human SOX6 promoter and exon 1
region (517 to IVS1þ 23) was generated and transfected in HeLa and
ATDC5 cells as reported previously25. For the COL2A1 promoter assay, a lu-
ciferase-reporter construct containing the four repeats of the 49 bp SOX9 en-
hancer and the basal promoter (from 183 to þ23) in the human COL2A1
gene was generated and transfected in the cells26.IMMUNOHISTOCHEMISTRYTissues from C57BL6 mouse embryos (E17.5) were ﬁxed in 4% parafor-
maldehyde/phosphate-buffered saline (PBS) overnight at 4C, embedded in
parafﬁn and cut into 5 mm sections. Sections were incubated overnight at
4C with primary antibodies to RelA (C-20) (1:200; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) and SOX9 (1:500; Santa Cruz Biotechnology),
as well as the non-immune serum as the control. The localizations were de-
tected with horseradish peroxidase-conjugated secondary antibodies (Prom-
ega, Madison, WI, USA).ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)RelA protein was prepared by in vitro translation using the TNT T7 Cou-
pled Reticulocyte Lysate System (Promega) and pCITE4 vector (Novagen,
Milwaukee, WI, USA) into which RelA complementary DNA was cloned.
The translation product was veriﬁed by Western blotting. Nuclear extracts
were prepared from undifferentiated and differentiated ATDC5 cells before
and after the culture with ITS for 3 weeks and Pi for 2 d, respectively.
EMSA was carried out using a DIG gel shift kit (Roche, Mannheim, Germany)
according to the manufacturer’s instructions. Binding reactions were incu-
bated for 30 min at room temperature. For competition analyses, 100-fold ex-
cess of unlabeled competitor probe was included in the binding reaction. For
the supershift experiments, 1 mL of the antibody to RelA (C-20) above was
added after 30 min of the binding reaction, and the reaction was incubated
for an additional 30 min at room temperature. Samples were loaded onto No-
vex 6% TBE gels (Invitrogen), and electrophoresed at 100 V for 60 min.CHROMATIN IMMUNOPRECIPITATION (ChIP) ASSAYThe ChIP assay was performed with a OneDay ChIP kit (Diagenode,
Liege, Belgium) according to the manufacturer’s instructions. In vivo cross-
linking was performed 2 d after the transfection of HeLa cells with EV,
RelA using FuGENE 6, and then the lysates were sonicated to shear geno-
mic DNA. For immunoprecipitation, an antibody to RelA and the control nor-
mal rabbit immunoglobulin G (IgG) were used. Two primer sets, one
spanning (478/239 bp) and the other not spanning (3781/3625 bp)
the identiﬁed NF-kB motif, were employed. PCR was performed using Ex
Taq (Takara Bio, Otsu, Japan) in the presence of 10% dimethyl sulfoxide.GENE TRANSFERFor transient gene transfer, 2 105 HeLa cells were cultured in 6-well
plates to subconﬂuency, and transfected with 1 mg of expression vector of
RelA or the control empty vector (EV) using FuGENE 6. After 48 h, total
mRNA of harvested cells was extracted and analyzed by real-time RT-
PCR as described below.
Production of retroviral vectors was performed as described previously27.
For retroviral gene transfer, 2 106 Plat-E cells were plated in 6-well plates,
transfected with 2 mg pMx vector of RelA or the control green ﬂuorescent pro-
tein (GFP) using FuGENE 6, and the conditioned medium was collected after
48 h. On the day before retroviral transfection, 3 105 of ATDC5 cells were
plated onto a 60-mm culture dish. For the transfection, 4 mL of the condi-
tioned medium containing the retrovirus was added to the cells with 32 mg
of polybrene. Selection of the retrovirus-introduced cells was started 48 h af-
ter transfection in the medium containing 10 mg/mL of blasticidin.REAL-TIME RT-PCRTotal RNA from cells was isolated with an RNeasy Mini kit (Qiagen, Hil-
den, Germany) according to the manufacturer’s instructions, and an aliquot
(1 mg) was reverse-transcribed with QuantiTect Reverse Transcription (Qia-
gen) to make single-stranded cDNA. Real-time RT-PCR was performed with
an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) using QuantiTect SYBR Green PCR Master Mix (Qiagen)
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thesized with a TOPO TA Cloning kit (Invitrogen, Carlsbad, CA, USA), ac-
cording to the manufacturer’s instructions. All reactions were run in
quadruplicate. Copy numbers of target gene messenger RNA (mRNA) in
each total RNA were calculated by reference to standard curves and were
adjusted to the human or mouse standard total RNA (ABI) with the human
GAPDH or rodent GAPDH as an internal control. The primer sequences
are available upon request.CHONDROCYTE DIFFERENTIATION ASSAYSFor the Alcian blue staining, the cells were ﬁxed with 10% (vol/vol) form-
aldehyde, and stained with 0.3% Alcian blue 8GS (Fluka, Buchs, Switzer-
land) in 0.1 N HCl. Alkaline phosphatase (ALP) staining was performed by
a solution containing 0.01% naphtol AS-MX phosphate disodium salt, 1%
N,N-dimethyl-formamide and 0.06% fast blue BB (Sigma). ALP activity
was measured with a Lab Assay ALP kit (Wako, Osaka, Japan).Human
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Fig. 1. Comparison of the proximal promoter sequences of the human, m
three species are denoted by white letters shaded in gray or black, respec
mouse genes. Putative binding motifs of transcription factorResultsIDENTIFICATION OF TRANSACTIVATORS OF THE SOX9
PROMOTER BY COMPARISON BETWEEN HUMAN AND
MOUSE GENESTo identify transcription factors that activate the SOX9
promoter, we initially performed exhaustive comparison of
the sequences of about 4 kb of the 50-end ﬂanking regions be-
tweenhumanandmousegenes, and found that the 1.0 kb up-
stream of the TSS was about 80% conserved between the
species. The sequence search identiﬁed the binding motifs
of NFAT, AP-1, NF-kB, Sp1, CREB/ATF, CCAAT, and
GATA in the highly-conserved regions (Fig. 1). The sequence
of themotifs at the proximal region showed good conservation
in the chick gene as well as in the human and mouse ones.–337
–539
AP-1
+9
TA-box
–130
CREB/ATF
–206
–278
–389
–460
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ouse and chick SOX9 genes. Conserved nucleotides in the two or
tively. An arrow shows the transcription start sites of the human and
s identiﬁed in highly-conserved regions are indicated.
1068 M. Ushita et al.: Transcriptional induction of SOX9 by NF-kB family member RelA in chondrogenic cellsWe therefore created expression vectors of the tran-
scription factors whose binding motifs were identiﬁed:
NFAT1, NFAT2, NFAT3, NFAT4, NFAT5, Fos, Jun, Fra-1,
RelA, RelB, Rel, p105, p50, p100, p52, ATF1, ATF2,
ATF4, ATF6, ATF7, CREB, C/EBPa, C/EBPb, C/EBPd,
C/EBP3, GATA-1, GATA-2, GATA-3, GATA-4, GATA-5,
and GATA-6; and transfected them in human non-
chondrogenic HeLa cells and mouse chondrogenic
ATDC5 cells with a luciferase-reporter construct contain-
ing the 50-end ﬂanking region (927/þ84) of the human
SOX9 gene (Fig. 2). Among the transcription factors,
the luciferase-reporter assay revealed that an NF-kB fam-
ily member RelA strongly activated the SOX9 promoter
activity in both HeLa and ATDC5 cells, causing us to
speculate that RelA is a potent transcriptional factor for
SOX9 induction.Relative lucifera
C/EBPα
0
EV
ATF1
ATF2
ATF4
ATF6
ATF7
CREB
NFAT2
NFAT1
NFAT3
NFAT4
NFAT5
C/EBPδ
C/EBPβ
C/EBPε
GATA-1
GATA-5
GATA-4
GATA-2
GATA-3
GATA-6
Fos
Fra-1
Jun
RelA
RelB
Rel
p50
p100
p52
p105
HeLa
100 200
Fig. 2. Luciferase assay for the human SOX9 promoter activity by the t
Human non-chondrogenic HeLa cells and mouse chondrogenic ATDC5
the proximal 50-end ﬂanking region (from 927 to þ84 bp relative to the TS
EV. Data are shown as means (bars) S.E.M. (error bars) of relative lucifer
4 wells/groIN VIVO LOCALIZATION OF RelA AND SOX9 IN THE LIMB
CARTILAGETo know the possible interaction between RelA and SOX9
in vivo, we then examined the expression patterns of RelA
and SOX9 in the limb cartilage of fetal mice (Fig. 3). Both
RelA and SOX9 were well co-localized in resting chondro-
cytes, as well as in pre-hypertrophic and hypertrophic chon-
drocytes, suggesting the molecular interaction between
RelA and SOX9 during the chondrocyte differentiation.IDENTIFICATION OF THE CORE REGION RESPONSIVE
TO RelA IN THE SOX9 PROXIMAL PROMOTERTo identify the region responsive to RelA in the human
SOX9 proximal promoter, we performed the deletion analy-
sis of the luciferase assay in HeLa and ATDC5 cellsse activity
0 100 200
ATDC5
ranscription factors whose binding motifs were identiﬁed in Fig. 1.
cells co-transfected with luciferase-reporter constructs containing
S) of the human SOX9 gene, and the effecter vectors or the control
ase activity (the ratio of the ﬁreﬂy activities to the renilla activities) for
up.
Fig. 3. Localizations of RelA and SOX9 by immunohistochemistry using the antibodies and the control non-immune serum in the proximal tibial
limb cartilage of fetal mice (E17.5). Inset boxes in the top panels indicate the regions of the respective lower ﬁgures. Yellow, blue, red and
green bars to the left of the panels indicate layers of resting, proliferative, pre-hypertrophic and hypertrophic zones, respectively. Scale
bar, 100 mm.
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50-deletions of the 927/þ84 fragment identiﬁed the de-
creases of the transcriptional activity between 289 and
202 bp, and between 202 and 127 bp in both cells
[Fig. 4(A)]. When we further compared the luciferase activity
of the tandem repeats of the distal (289/203 bp) and
proximal (202/128 bp) elements, only the distal re-
sponded to RelA in the repeat number-dependent manner,
indicating that the region between 289 and 203 bp con-
tains a core region responsive to RelA [Fig. 4(B)]. In fact,
the identiﬁed 289/203 bp element contained a consen-
sus sequence of the NF-kB binding motif (HGGARNYYCC)
at 252/243 bp (TGGAAGTCCC), which was the only
fully-matched sequence in the 1 kb SOX9 promoter.
We therefore prepared the 39 bp (266/228 bp) ele-
ment containing the NF-kB motif for further analyses
[Fig. 5(A)]. To examine the core responsive region in the el-
ement, we created two base mutations within the NF-kB
binding motif, and further performed luciferase assay of tan-
dem repeats of the wild-type and mutated elements in HeLa
and ATDC5 cells. The repeat number-dependent transacti-
vation of the wild-type element by RelA was suppressed by
the mutagenesis in both cell types, conﬁrming that theNF-kB binding motif is the core region responsive to RelA
[Fig. 5(A)].
EMSA revealed the complex formation of the in vitro-trans-
lated RelA protein with the 39 bp element above [Fig. 5(B),
lane 2]. Mutagenesis analyses in the element showed that
the complex formation was abolished by mutations inside
the NF-kB motif (m1 and m2), but not by outside mutations
(m3) [Fig. 5(B), lanes 3e5]. Cold competition with excess
amount of the unlabeled wild-type and outside mutation
probes suppressed the complex formation, while that with
the unlabeled inside mutation probes did not affect it
[Fig. 5(B), lanes 6e9]. The binding between RelA and the
NF-kB motif was conﬁrmed by the complex formation of the
39 bp probewith nuclear extracts fromATDC5 cells. Interest-
ingly, the complex formation was stronger by nuclear ex-
tracts from differentiated ATDC5 cells after the culture with
differentiation medium than those of undifferentiated cells
before the culture [Fig. 5(B), lanes 14 and 15]. Both com-
plexes with the in vitro-translated RelA protein [Fig. 5(B),
lane 12] and the ATDC5 nuclear extracts [Fig. 5(B), lane
18] underwent supershifts by addition of an antibody to
RelA. These results demonstrate the speciﬁc binding be-
tween RelA and the NF-kB motif in the SOX9 promoter.
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Fig. 4. (A) Identiﬁcation of the region responsive to RelA by the deletion analysis of the luciferase assay in HeLa and ATDC5 cells. The cells
with luciferase-reporter constructs containing the abovementioned 927/þ84 region of the human SOX9 gene and the series of deletion frag-
ments were co-transfected with RelA or the control EV. (B) Luciferase assays of the tandem repeats of the distal (289/203 bp relative to the
TSS) and proximal (202/128 bp) elements that were identiﬁed in the deletion analysis above in HeLa and ATDC5 cells co-transfected with
RelA or the control EV. The loci of consensus binding motifs that were identiﬁed by the present and previous studies (NF-kB, Sp1, CREB, and
CCAAT) are indicated by open arrowheads. Data are shown as means (bars)  S.E.M. (error bars) of relative luciferase activity for
4 wells/group.
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SOX9 promoter including the NF-kB motif [Fig. 5(C), left].
The speciﬁcity of the binding was conﬁrmed because it
was not immunoprecipitated by the non-immune IgG
[Fig. 5(C), left], and no ampliﬁcation was seen with a primer
set that does not span the NF-kB motif [Fig. 5(C), right].FUNCTIONAL ROLE OF RelA IN CHONDROGENIC
DIFFERENTIATIONFinally, we investigated the involvement of RelA in
chondrogenic differentiation. Among the NF-kB familymembers transfected in HeLa cells and ATDC5 cells,
luciferase assays revealed that RelA transfection strongly
stimulated the promoter activities of SOX6 and COL2A1,
the representative chondrogenic markers besides SOX9
[Fig. 6(A)].
When RelA or the control EV was transiently transfected
into HeLa cells, the RelA overexpression stimulated the
mRNA levels of endogenous SOX9, SOX6, and COL2A1
[Fig. 6(B)]. To further investigate the function of RelA in
chondrogenic differentiation, we established stable lines of
ATDC5 cells with retroviral overexpression of RelA or the
control GFP vector, and cultured them in the chondrogenic
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Fig. 5. (A) The 39 bp element (265/227 bp) containing the putative NF-kB motif (251/242 bp, underlined) in the identiﬁed region
(wild-type; WT) and that with two base mutations at 243 and 249 bp (black boxes) within the NF-kB motif (m1). Luciferase assays of
the tandem repeats of the WT and m1 elements in HeLa and ATDC5 cells co-transfected with RelA or the control EV. Data are shown as
means (bars) S.E.M. (error bars) of relative luciferase activity for 4 wells/group. (B) EMSA for binding of the in vitro-translated RelA protein
(Rp; lanes 1e12) or nuclear extract (Ne; lanes 13e18) with the WT or the mutated probes of the 39 bp element (265/227 bp) above. Rl
denotes reticulocyte lysate without the transcriptional/translational template. Mutations were created inside (m1 for double mutations and m2
for a single mutation) and outside (m3) the NF-kB motif. Cold competition with 100-fold excess of unlabeled WT or the mutated probes is also
presented. Binding to the probe was compared between nuclear extracts of ATDC5 cells before (NeB) and after (NeA) the chondrogenic dif-
ferentiation by ITS and Pi. The arrowhead indicates the shifted bands of the RelAeDNA probe complex. RA and IgG denote an antibody to
RelA and non-immune IgG as the control, respectively. (C) ChIP assay for speciﬁc binding of RelA to the NF-kB motif. Cell lysates of HeLa
cells with no transfection (), transfected with EV, or RelA were ampliﬁed by a primer set spanning the NF-kB motif (478/239 bp, left panel)
or not spanning the motif (3781/3625 bp, right panel) before (input) and after immunoprecipitation with an antibody to RelA (a-RelA) or the
control non-immune IgG (a-IgG).
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1073Osteoarthritis and Cartilage Vol. 17, No. 8differentiation medium [Fig. 6(C)]. In addition to the mRNA
levels of SOX9, SOX6, COL2A1, the chondrogenic differen-
tiation markers Alcian blue and ALP activity were stimulated
by the RelA overexpression. The raw values of SOX9,
SOX6, and COL2A1 mRNA levels normalized by G3PDH
in the control HeLa cells were 1999 29, 486 90, and
21 2 copies/mg of total RNA [Fig. 6(B)], while those in
the control ATDC5 cells were 118 8, 356 11, and
6983 214 copies/mg of total RNA, respectively
[Fig. 6(C)], indicating that HeLa cells express negligible
level of COL2A1 despite higher levels of SOX9 and SOX6
than ATDC5 cells. These results indicate that RelA func-
tions as an inducer of chondrogenic differentiation, probably
via the SOX9 transactivation.
Discussion
The present comparison of the promoters between
human and mouse SOX9 genes found an NF-kB family
member RelA to be a transcription factor of SOX9. We fur-
ther identiﬁed an NF-kB binding motif around 250 bp as
the core region responsive to RelA in the human SOX9
proximal promoter. In several previous studies, the se-
quences of the mouse and human SOX9 genes were com-
pared and functional analyses of the SOX9 promoter were
made. Morishita et al. identiﬁed a 30-bp region in the ﬁrst in-
tron as an ATDC5-speciﬁc enhancer, although the related
transcriptional regulation remains unclear28. Kanai and
Koopman showed that the region between 193 and
73 bp is essential for the sex- and tissue-speciﬁc expres-
sion of the mouse SOX9 gene29. These ﬁndings were con-
sistent with those of a later study by Colter et al. on the
human SOX9 promoter in which activity decreased when
a deletion was made past position 172 bp30. In the region,
they identiﬁed two CCAAT motifs that are important for the
SOX9 promoter activity in chondrogenic cells. In the present
deletion analysis of the luciferase assay, these motifs are
located between 127 and 91 bp and between 91 and
50 bp [the top schema in Fig. 4(B)]. Although the transac-
tivity induced by RelA did not differ between the regions, the
baseline activity without the RelA stimulation was actually
decreased between them [Fig. 4(A)]. This conﬁrms the reg-
ulation of SOX9 transactivity by C/EBP proteins through its
interaction with the two CCAAT motifs located more proxi-
mal to the present NF-kB motif in the SOX9 promoter. In
fact, C/EBP proteins showed potent transactivation of
SOX9 in both HeLa and ATDC5 cells (Fig. 2). More re-
cently, the same group reported that the human SOX9 prox-
imal promoter is also regulated by the cyclic-AMP response
element binding (CREB) protein and Sp131. In the present
deletion analysis, the binding motifs are located between
202 and 128 bp, which we identiﬁed as the proximal
element [the top schema in Fig. 4(B)]. Here again, the base-
line transactivity was decreased as well as the RelA-
induced activity. In the tandem-repeat experiments, the
baseline transactivity was increased dependent on theFig. 6. (A) Promoter activities of SOX6 and COL2A1 by the NF-kB family
with the luciferase-reporter construct containing the SOX6 promoter fragm
promoter fragment (four repeats of the 49 bp SOX9 enhancer and the bas
the NF-kB family factors or the control EV. Data are shown as means (ba
ﬁreﬂy activities to the renilla activities) for 4 wells/group. (B) mRNA levels
RT-PCR in HeLa cells that were transiently transfected with RelA or the c
relative mRNA level as compared to the EV-transfected cells for 3 wells/g
Alcian blue staining, ALP staining and activity (relative to control) in stable
green ﬂuorescence protein (GFP) and in non-transfected parental cells
mRNA data are shown as means (bars) S.E.M. (error bars) as comprepeat number of the proximal element, though not as
strongly as that of the distal element (202/128) under
the RelA stimulation [Fig. 4(B)]. Interestingly, the decrease
in the deletion analysis and the increase in the tandem-
repeat analysis of the proximal element were equivalently
seen between the presence and absence of the RelA stim-
ulation, while those of the distal element were apparent only
under the RelA stimulation (Fig. 4). These indicate that the
identiﬁed NF-kB motif in the distal element is speciﬁc to
the RelA stimulation, while the proximal element including
the CREB and Sp1 motifs functions as a basal regulatory
region in the SOX9 proximal promoter.
The RelA overexpression enhanced the promoter activi-
ties and the endogenous mRNA levels of SOX6 and
COL2A1 in HeLa and ATDC5 cells (Fig. 6). These may
be at least partly mediated by the RelA effect on the
SOX9 transactivation, since SOX9 is a crucial transcrip-
tional activator of SOX6 and COL2A14e6,10. Although the
RelA overexpression enhanced chondrogenic differentia-
tion shown by Alcian blue staining and ALP activity in differ-
entiated ATDC5 cells after the stimulation by ITS and Pi
[Fig. 6(C)], this was not reproducible in undifferentiated
ATDC5 cells without the stimulation (data not shown). Con-
sidering that the promoter assays were performed in
ATDC5 cells without the differentiation stimulation, there is
a discrepancy between endogenous mRNA levels and ex-
ogenous promoter activities of SOX9, SOX6 and COL2A1
in the RelA actions on undifferentiated ATDC5 cells. This
might be due to post-transcriptional negative regulation
that was speciﬁc to endogenous mRNAs or the chromatin
regulation occurring only in a genomic context, which are
speciﬁc to undifferentiated ATDC5 cells. In fact, EMSA us-
ing nuclear extracts from ATDC5 cells revealed that com-
plex formation with the NF-kB probe was much stronger
in extracts from differentiated cells than in those from undif-
ferentiated cells [Fig. 5(B), lanes 14 and 15]. Contrarily, our
previous study has shown that the overexpression of SOX
trio or the SOX9 alone potently stimulated chondrogenic dif-
ferentiation even from non-chondrogenic cells14, indicating
that the RelA may not induce sufﬁciently high SOX9 levels
to force chondrogenic differentiation in the absence of
additional stimulation.
Although the present study focused on a region within
1 kb of the 50-end ﬂanking region of the SOX9 gene and
identiﬁed RelA as the potent transactivator of the limited re-
gion, there are surely more distant regions that are critical
for the SOX9 expression. The fact that translocation break-
points in campomelic dysplasia patients have been map-
ped 50 kb- or more distant from SOX913,32 indicates the
large genomic environment regulating SOX9 expression
in vivo. In mice as well, suppression of limb outgrowth by
the blockage of the NF-kB pathway was shown to be due
to defects in ﬁbroblast growth factor (FGF) signal which
caused a failure in mesenchymaleepithelial communica-
tion, rather than to a defect in chondrogenesis20,33.
In addition to the abovementioned signals that directlymembers in HeLa and ATDC5 cells. The cells were co-transfected
ent (517 to IVS1þ 23 in the human SOX6 gene) or the COL2A1
al promoter from 183 to þ23 bp in the human COL2A1 gene), and
rs) S.E.M. (error bars) of relative luciferase activity (the ratio of the
of endogenous SOX9, SOX6, and COL2A1 determined by real-time
ontrol EV. Data are shown as means (bars) S.E.M. (error bars) of
roup. (C) mRNA levels of endogenous SOX9, SOX6, and COL2A1,
lines of ATDC5 cells retrovirally transfected with RelA or the control
() after culture for 3 weeks with ITS and 2 d with Pi. The relative
ared to the non-transfected parental cells () for 3 wells/group.
1074 M. Ushita et al.: Transcriptional induction of SOX9 by NF-kB family member RelA in chondrogenic cellsactivate the putative motifs such as CCAAT, CREB, and
Sp1 within the 1 kb promoter, there are several pathways
known to induce the SOX9 expression. FGFs have been
shown to up-regulate SOX9 mRNA expression in chondro-
cytes through a MAP kinase pathway34. Bone morphoge-
netic proteins and hedgehog family members enhance
SOX9 expression under certain conditions, while retinoic
acid exhibits mixed results8,35e37. Hence, we surmise that
RelA is not the principal transactivator of SOX9, but is
a member of complicated molecular network for the trans-
activation. Addition of other signals to RelA will be needed
to achieve strong SOX9 induction and efﬁcient chondro-
genic differentiation.
Proinﬂammatory cytokines interleukin-1 (IL-1) and tumor
necrosis factor (TNF)-a are known to be representative
ligands for the NF-kB signal38e41. A previous report showed
that IL-1 and TNF-a caused a suppression of SOX9 expres-
sion in chondrogenic cells, which may explain the deleteri-
ous role of the cytokines in cartilage degenerative
disorders such as rheumatoid arthritis and osteoarthritis42.
Interestingly, the report indicated that the SOX9 suppres-
sion is at least partly mediated by the NF-kB signal induced
by the cytokines. Furthermore, a recent study showed that
silencing of IKKb enhanced the accumulation of glycosami-
noglycan in conjunction with increased SOX9 expression in
human osteoarthritis chondrocytes43. These indicate the
down-regulation of SOX9 by the NF-kB signal, which seems
contradictory to the present results showing the positive re-
lationship between them. A previous study, however, has
shown that the SOX9 suppression by NF-kB occurs not at
the transcriptional level, but at the post-transcriptional level
through the RNA sequence-dependent mechanism38. At
the transcriptional level as well, there may be pathways
other than NF-kB in the SOX9 suppression by the proin-
ﬂammatory cytokines, since the human promoter study
above has shown that IL-1 down-regulated SOX9 promoter
activity through a reduction of Sp1 binding to the proximal
promoter in chondrocytes31. Hence, the NF-kB and SOX9
signals may regulate chondrogenic differentiation and skel-
etal development via complicated mechanisms by various
kinds of interactions with each other.
Regarding RelA, to date a description of the in vivo
function has been limited to the embryonic lethality of
the homo-knockout mice. Since a recent report demon-
strated that Nkx3.2 supports chondrocyte survival by ac-
tivating RelA via a ligand-independent mechanism44,
RelA might possibly function to maintain the chondro-
genic phenotype through constitutive activation of
SOX9. Further understanding of the molecular network
related to the RelA/SOX9 axis will lead to elucidation of
the mechanism underlying chondrogenic differentiation
and cartilage formation under physiological and patholog-
ical conditions.Conﬂict of interest
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